Plasma Xanthine Oxidase Activity Is Predictive of Cardiovascular Disease in Patients with Chronic Kidney Disease, Independently of Uric Acid Levels

Nephron

Volumn 131, Issue 3, 2015, Pages 167-174

  Gondouin, Bertrand ^a,b,e   Jourde Chiche, Noemie ^a,b   Sallee, Marion ^a,b   Dou, Laetitia ^b   Cerini, Claire ^b   Loundou, Anderson ^d   Morange, Sophie ^d   Berland, Yvon ^a   Burtey, Stephane ^a,b   Brunet, Philippe ^a,b   Guieu, Regis ^c   Dussol, Bertrand ^a,b  

^a Centre de Nephrologie et Transplantation Rénale   (France)

^b INSERM   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^e HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Cardiovascular; End stage renal disease; Kidney disease; Mortality; Oxidant stress; Uric acid

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE PHOSPHATE; ALLOPURINOL; ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ASCORBIC ACID; FEBUXOSTAT; GLUTATHIONE REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOSINE PHOSPHATE; ISCHEMIA MODIFIED ALBUMIN; MALONALDEHYDE; PURINE; SELENIUM; SUPEROXIDE DISMUTASE; URIC ACID; XANTHINE OXIDASE; ZINC; PURINE DERIVATIVE;

ADULT; AGE; AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME SUBSTRATE; ERYTHROCYTE; FEMALE; FOLLOW UP; GENDER; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PURINE METABOLISM; SELENIUM BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; VITAMIN BLOOD LEVEL; ZINC BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; MORTALITY; OXIDATION REDUCTION REACTION; RENAL REPLACEMENT THERAPY; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PURINES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; URIC ACID; XANTHINE OXIDASE;

EID: 85027945188     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000441091     Document Type: Article

References (37)

1. Wheeler DC: Cardiovascular disease in patients with chronic renal failure. Lancet 1996; 348: 1673-1674.
2. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B: Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293: 1737-1745.
3. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P: Proteinbound toxins-update 2009. Semin Dial 2009; 22: 334-339.
4. Himmelfarb J: Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial 2009; 22: 636-643.
5. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J: Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-1016.
6. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313.
7. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, London GM, Jungers P: Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005; 45: 39-47.
8. Jung HH, Choi DH, Lee SH: Serum malondialdehyde and coronary artery disease in hemodialysis patients. Am J Nephrol 2004; 24: 537-542.
9. Suliman ME, Johnson RJ, Garcia-Lopez E, Qureshi AR, Molinaei H, Carrero JJ, Heimburger O, Barany P, Axelsson J, Lindholm B, Stenvinkel P: J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006; 48: 761-771.
10. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Levey AS, Menon V: Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009; 53: 796-803.
11. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ: Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-1742.
12. Takahashi N, Morimoto S, Okigaki M, Seo M, Someya K, Morita T, Matsubara H, Sugiura T, Iwasaka T: Decreased plasma level of vitamin C in chronic kidney disease: comparison between diabetic and non-diabetic patients. Nephrol Dial Transplant 2011; 26: 1252-1257.
13. Tonelli M, Wiebe N, Hemmelgarn B, Klarenbach S, Field C, Manns B, Thadhani R, Gill J; Alberta Kidney Disease Network: Trace elements in hemodialysis patients: A systematic review and meta-analysis. BMC Med 2009; 7: 25.
14. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, Zingraff J, Verger C, Jungers P, Descamps-Latscha B: Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996; 21: 845-853.
15. Filiopoulos V, Hadjiyannakos D, Takouli L, Metaxaki P, Sideris V, Vlassopoulos D: Inflammation and oxidative stress in end-stage renal disease patients treated with hemodialysis or peritoneal dialysis. Int J Artif Organs 2009; 32: 872-882.
16. Kotur-Stevuljevi J, Peco-Anti A, Spasi S, Stefanovi A, Paripovi D, Kosti M, Vasi D, Vujovi A, Jeli-Ivanovi Z, Spasojevi-Kalimanovska V, Kornic-Ristovski D: Hyperlipidemia, oxidative stress, and intima media thickness in children with chronic kidney disease. Pediatr Nephrol 2013; 28: 295-303.
17. Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, Collinson PO, Brecker SJ: Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006; 47: 493-502.
18. Agarwal R: Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol 2003; 284:F863-F869.
19. Kuchta A, Pacanis A, Kortas-Stempak B, Cwikliska A, Zitkiewicz M, Renke M, Rutkowski B: Estimation of oxidative stress markers in chronic kidney disease. Kidney Blood Press Res 2011; 34: 12-19.
20. Aveles PR, Criminacio CR, Goncalves S, Bignelli AT, Claro LM, Siqueira SS, Nakao LS, Pecoits-Filho R: Association between biomarkers of carbonyl stress with increased systemic inflammatory response in different stages of chronic kidney disease and after renal transplantation. Nephron Clin Pract 2010; 116:c294-c299.
21. Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A: Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications. J Cardiol 2012; 59: 235-242.
22. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, Arroyo D, Luno J: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388-1393.
23. Johnson RJ, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritz E: Uric acid and chronic kidney disease: which is chasing which Nephrol Dial Transplant 2013; 28: 2221-2228.
24. Kao MP, Ang DS, Gandy SJ, Nadir MA, Houston JG, Lang CC, Struthers AD: Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2011; 22: 1382-1389.
25. Ng KP, Stringer SJ, Jesky MD, Yadav P, Athwal R, Dutton M, Ferro CJ, Cockwell P: Allopurinol is an independent determinant of improved arterial stiffness in chronic kidney disease: A cross-sectional study. PLoS One 2014; 9:e91961.
26. Chung AW, Yang HH, Kim JM, Sigrist MK, Brin G, Chum E, Gourlay WA, Levin A: Arterial stiffness and functional properties in chronic kidney disease patients on different dialysis modalities: An exploratory study. Nephrol Dial Transplant 2010; 25: 4031-4041.
27. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT: Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: A prospective cohort study. Arch Intern Med 2004; 164: 1546-1551.
28. Latif W, Karaboyas A, Tong L, Winchester JF, Arrington CJ, Pisoni RL, Marshall MR, Kleophas W, Levin NW, Sen A, Robinson BM, Saran R: Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol 2011; 6: 2470-2477.
29. Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, Perez de Jose A, Cedeno S, Linares T, Luno J: Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis 2015; 65: 543-549.
30. Mallamaci F, Testa A, Leonardis D, Tripepi R, Pisano A, Spoto B, Sanguedolce MC, Parlongo RM, Tripepi G, Zoccali C: A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: A family-based study. Am J Kidney Dis 2015; 65: 294-302.
31. Choi YJ, Yoon Y, Lee KY, Hien TT, Kang KW, Kim KC, Lee J, Lee MY, Lee SM, Kang DH, Lee BH: Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J 2014; 28: 3197-3204.
32. Sjoberg B, Anderstam B, Suliman M, Alvestrand A: Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD. Am J Kidney Dis 2006; 47: 60-71.
33. Kocot J, Kieczykowska M, Dbrowski W, Piat J, Rudzki S, Musik I: Total antioxidant status value and superoxide dismutase activity in human colorectal cancer tissue depending on the stage of the disease: A pilot study. Adv Clin Exp Med 2013; 22: 431-437.
34. Rahn-Chique K, Carrion N, Murillo M: [Determination of copper, magnesium and zinc in mononuclear leukocytes by flame atomic absorption spectrometry]. Invest Clin 2012; 53: 342-352.
35. Martinez-Hervas S, Real JT, Ivorra C, Priego A, Chaves FJ, Pallardo FV, Vina JR, Redon J, Carmena R, Ascaso JF: Increased plasma xanthine oxidase activity is related to nuclear factor kappa beta activation and inflammatory markers in familial combined hyperlipidemia. Nutr Metab Cardiovasc Dis 2010; 20: 734-739.
36. Dussol B, Fenouillet E, Brunet P, Purgus R, Sauze N, Carrega L, Mercier L, Zouher I, Bechis G, Berland Y, Guieu R: Kinetic study of adenosine concentrations and the expression of adenosine deaminase in mononuclear cells during hemodialysis. Kidney Int 2004; 66: 1640-1646.
37. Levey AS, Greene T, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG, Klahr S: Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown Modification of diet in renal disease study group. J Am Soc Nephrol 1999; 10: 2426-2439.